PNPLA3 and metabolic dysfunction-associated steatotic liver disease: An in vitro study demonstrated that the efficacy of resmetirom, a thyroid hormone receptor beta agonist that was recently approved by the FDA for the treatment of MASLD, was influenced by PNPLA3 variants [42].